Your browser is no longer supported. Please, upgrade your browser.
Settings
IMMU Immunomedics, Inc. daily Stock Chart
IMMU [NASD]
Immunomedics, Inc.
Index- P/E- EPS (ttm)-1.53 Insider Own1.00% Shs Outstand172.99M Perf Week2.38%
Market Cap4.39B Forward P/E- EPS next Y-0.92 Insider Trans61.28% Shs Float164.32M Perf Month8.22%
Income-210.10M PEG- EPS next Q-0.22 Inst Own71.60% Short Float14.46% Perf Quarter50.83%
Sales2.40M P/S1830.81 EPS this Y-135.30% Inst Trans0.81% Short Ratio9.00 Perf Half Y64.19%
Book/sh0.44 P/B57.73 EPS next Y27.00% ROA-98.60% Target Price36.00 Perf Year181.28%
Cash/sh2.07 P/C12.25 EPS next 5Y- ROE- 52W Range7.17 - 26.48 Perf YTD57.18%
Dividend- P/FCF- EPS past 5Y-44.67% ROI-200.90% 52W High-4.08% Beta1.73
Dividend %- Quick Ratio3.90 Sales past 5Y-37.60% Gross Margin72.70% 52W Low254.25% ATR0.94
Employees138 Current Ratio3.90 Sales Q/Q-61.50% Oper. Margin- RSI (14)64.11 Volatility2.49% 3.81%
OptionableYes Debt/Eq2.78 EPS Q/Q61.10% Profit Margin- Rel Volume0.49 Prev Close25.47
ShortableYes LT Debt/Eq2.78 EarningsAug 08 AMC Payout- Avg Volume2.64M Price25.40
Recom1.50 SMA204.03% SMA5011.18% SMA20053.87% Volume1,290,255 Change-0.27%
Jun-07-18Initiated B. Riley FBR, Inc. Buy $53
May-05-17Upgrade Wells Fargo Market Perform → Outperform
Oct-06-16Resumed Jefferies Buy
Jun-21-16Downgrade Wells Fargo Outperform → Market Perform
May-06-16Upgrade Jefferies Hold → Buy
Dec-04-15Downgrade Wells Fargo Outperform → Market Perform
Jul-29-15Downgrade Jefferies Buy → Hold
Aug-27-14Downgrade R. F. Lafferty Buy → Neutral $4
Jan-08-14Initiated Chardan Capital Markets Buy $9
Oct-02-13Reiterated Oppenheimer Outperform $6 → $8
Sep-10-13Initiated R. F. Lafferty Buy $8
Jun-03-13Initiated WallachBeth Buy $6
Aug-31-11Initiated Summer Street Research Buy $8
Jul-28-11Initiated Summer Street Research Buy $8
Jul-13-11Resumed Brean Murray Buy $8
May-17-11Initiated Oppenheimer Outperform $6
Feb-23-11Initiated Wedbush Outperform $6
Jul-03-07Initiated Brean Murray Buy $8
Feb-20-07Initiated Lazard Capital Buy $6
Jul-18-18 08:00AM  FDA Accepts Biologics License Application for Filing and Grants Priority Review for Sacituzumab Govitecan for the Treatment of Metastatic Triple-negative Breast Cancer GlobeNewswire
Jul-11-18 07:35AM  Complimentary Technical Snapshots on Incyte and Three More Biotech Stocks ACCESSWIRE
Jun-27-18 10:42AM  How Financially Strong Is Immunomedics Inc (NASDAQ:IMMU)? Simply Wall St.
Jun-21-18 04:42PM  [$$] Immunomedics Chairman Buys $19M More in Stock Barrons.com
08:20AM  Today's Research Reports on Trending Tickers: ACADIA Pharmaceuticals and Immunomedics ACCESSWIRE
Jun-15-18 11:39AM  Immunomedics Announces Closing of Public Offering of Common Stock GlobeNewswire
Jun-13-18 08:00AM  Immunomedics Announces Pricing of Public Offering of Common Stock GlobeNewswire
Jun-12-18 02:30PM  The Charts of Immunomedics Look Very Bullish Now TheStreet.com
08:47AM  Benzinga's Daily Biotech Pulse: Galmed Rips Higher On Positive NASH Data, Enzo Biochem Falls On Earnings, Pfenex Licenses Osteoporosis Candidate Benzinga
Jun-11-18 04:13PM  Immunomedics Announces Proposed Public Offering of Common Stock GlobeNewswire
03:48PM  After-hours buzz: RH, PLAY and more CNBC
Jun-05-18 08:49AM  Immunomedics (IMMU) Soars: Stock Adds 10.3% in Session Zacks
08:20AM  Today's Research Reports on Stocks to Watch: Genomic Health and Immunomedics ACCESSWIRE
Jun-04-18 04:33PM  Why Fossil Group, Companhia Siderurgica Nacional, and Immunomedics Jumped Today Motley Fool +10.26%
04:32PM  Why A Tie-Up With Clovis Helped This Biotech Spike To An 18-Year High Investor's Business Daily
03:20PM  Why Data at ASCO 2018 Sent Immunomedics Shares Soaring Today Motley Fool
01:18PM  5 Biotech Stocks Moving On ASCO Presentations Benzinga
08:00AM  Immunomedics Provides Business Update at the ASCO 2018 Investor Event GlobeNewswire
Jun-03-18 08:00PM  Clovis Oncology and Immunomedics Announce Planned Clinical Collaboration to Study Combination Therapies in Metastatic Triple-Negative Breast and Urothelial Cancers GlobeNewswire
10:15AM  Immunomedics Reveals Promising Data for Sacituzumab Govitecan in Patients Heavily Pretreated for Metastatic Estrogen Receptor-Positive Breast Cancer GlobeNewswire
Jun-01-18 08:00AM  Immunomedics Announces Pivotal Study of Sacituzumab Govitecan in Patients With Locally Advanced or Metastatic Urothelial Cancer GlobeNewswire
May-30-18 08:00AM  Immunomedics to Present at Jefferies 2018 Global Healthcare Conference GlobeNewswire
May-21-18 08:00AM  Immunomedics Submits Biologics License Application For Sacituzumab Govitecan To The U.S. Food and Drug Administration GlobeNewswire
May-18-18 04:03AM  Edited Transcript of IMMU earnings conference call or presentation 9-May-18 9:00pm GMT Thomson Reuters StreetEvents
May-17-18 12:43PM  Immunomedics Inc (NASDAQ:IMMU): Time For A Financial Health Check Simply Wall St. +7.12%
08:00AM  Today's Research Reports on Trending Tickers: Immunomedics and Rite Aid ACCESSWIRE
May-16-18 05:01PM  Immunomedics Announces Promising Data of Sacituzumab Govitecan in Estrogen Receptor-Positive Metastatic Breast Cancer GlobeNewswire
May-09-18 04:24PM  Immunomedics: Fiscal 3Q Earnings Snapshot Associated Press
04:00PM  Immunomedics Announces Third Quarter Fiscal 2018 Results and Provides Corporate Update GlobeNewswire
07:30AM  Analysis: Positioning to Benefit within Entergy, Schneider National, C.H. Robinson Worldwide, PTC Therapeutics, Guess?, and Immunomedics  Research Highlights Growth, Revenue, and Consolidated Results GlobeNewswire
May-02-18 12:01PM  Harry Boxers four biotech stocks to watch today MarketWatch
08:00AM  Immunomedics to Report Third Quarter Fiscal 2018 Results and Host Conference Call and Webcast on May 9, 2018 GlobeNewswire
May-01-18 08:45AM  Immunomedics (IMMU) in Focus: Stock Moves 7.9% Higher Zacks
08:10AM  Todays Research Reports on Stocks to Watch: Heat Biologics and Immunomedics ACCESSWIRE
Apr-25-18 12:15PM  Immunomedics Announces Oral Presentation of Sacituzumab Govitecan in Hormone Receptor-Positive (HR+) Metastatic Breast Cancer (mBC) at 2018 American Society of Clinical Oncology (ASCO) Annual Meeting GlobeNewswire
Apr-17-18 10:21AM  When Will Immunomedics Inc (NASDAQ:IMMU) Become Profitable? Simply Wall St.
Apr-13-18 08:20AM  Todays Research Reports on Trending Tickers: Exact Sciences and Immunomedics ACCESSWIRE
Apr-11-18 08:30AM  Todays Research Reports on Trending Tickers: Neuralstem and Immunomedics ACCESSWIRE
Apr-09-18 08:00AM  Immunomedics Appoints Dr. Robert Iannone Head of Research & Development and Chief Medical Officer GlobeNewswire
Mar-27-18 08:25AM  Todays Research Reports on Trending Tickers: ACADIA Pharmaceuticals and Immunomedics ACCESSWIRE
Mar-05-18 08:00AM  Immunomedics to Present at Cowen and Company 38th Annual Health Care Conference GlobeNewswire
Feb-26-18 06:06PM  Edited Transcript of IMMU earnings conference call or presentation 8-Feb-18 10:00pm GMT Thomson Reuters StreetEvents
Feb-15-18 08:00AM  Immunomedics to Participate in RBC Capital Markets 2018 Global Healthcare Conference GlobeNewswire
07:30AM  Fennec Pharma (FENC): The Most Likely Acquisition Target in Healthcare with 200-300% Upside? ACCESSWIRE
Feb-14-18 07:30AM  Blog Exposure - FDA Accepts Amicus Therapeutics NDA for Migalastat for Treatment of Fabry Disease ACCESSWIRE
Feb-13-18 03:49PM  8 Companies That Could Disappear by 2019 InvestorPlace
Feb-09-18 05:01AM  Immunomedics reports 2Q loss Associated Press
Feb-08-18 04:15PM  Immunomedics Announces Second Quarter Fiscal 2018 Results and Provides Corporate Update GlobeNewswire
Feb-06-18 08:00AM  Immunomedics to Report Second Quarter Fiscal 2018 Results and Host Conference Call and Webcast on February 8, 2018 GlobeNewswire
Jan-31-18 08:20AM  New Research: Key Drivers of Growth for Cavco Industries, National Commerce, The Providence Service, Cisco, Immunomedics, and Emergent Biosolutions Factors of Influence, Major Initiatives and Sustained Production GlobeNewswire
Jan-17-18 07:00AM  Best ETFs for 2018: The SPDR S&P Biotech ETF (XBI) Will Continue to Rock InvestorPlace
Jan-11-18 08:00AM  Immunomedics Announces Agreement with University of Wisconsin Carbone Cancer Center to Expand Sacituzumab Govitecan (IMMU-132) into Prostate Cancer GlobeNewswire
Jan-10-18 08:00AM  Todays Research Reports on Stocks to Watch: Immunomedics, Inc. and Axsome Therapeutics ACCESSWIRE
Jan-08-18 08:30AM  Immunomedics and Royalty Pharma Announce Royalty Funding and Stock Purchase Agreements Totalling $250 Million GlobeNewswire
Jan-04-18 08:45AM  Immunomedics to Present at the 36th Annual J.P. Morgan Healthcare Conference GlobeNewswire
Dec-28-17 11:34AM  Harry Boxer: These two marijuana stocks are climbing higher MarketWatch
Dec-22-17 11:41AM  ETFs with exposure to Immunomedics, Inc. : December 22, 2017 Capital Cube +6.08%
Dec-21-17 12:23PM  BlackBerry Among Four Stocks Breaking Out Forbes
Dec-13-17 07:02AM  SHAREHOLDER ALERT: Purcell Julie & Lefkowitz LLP Is Investigating Immunomedics, Inc. for Potential Breaches Of Fiduciary Duty By Its Board of Directors PR Newswire
Dec-11-17 01:59PM  ETFs with exposure to Immunomedics, Inc. : December 11, 2017 Capital Cube
Dec-08-17 01:59PM  5 Cheap Biotech Stocks to Snag on the Bounce InvestorPlace
07:45AM  Immunomedics' Data Is Good News for Seattle Genetics, Too Motley Fool
07:16AM  Immunomedics, Inc. breached its 50 day moving average in a Bullish Manner : IMMU-US : December 8, 2017 Capital Cube
Dec-07-17 08:10AM  Todays Research Reports on Stocks to Watch: Immunomedics and Valeant Pharmaceuticals ACCESSWIRE +16.16%
Dec-06-17 03:58PM  Why Immunomedics, Inc. Is Soaring Today Motley Fool +13.00%
12:10PM  Immunomedics Announces Updated Results With Sacituzumab Govitecan (IMMU-132) In Patients With Relapsed Or Refractory Metastatic Triple-Negative Breast Cancer (mTNBC) GlobeNewswire
Nov-30-17 02:00PM  ETFs with exposure to Immunomedics, Inc. : November 30, 2017 Capital Cube
Nov-29-17 08:04AM  Immunomedics, Inc. :IMMU-US: Earnings Analysis: Q1, 2018 By the Numbers : November 29, 2017 Capital Cube
Nov-28-17 08:05AM  Immunomedics, Full Study Data to be Presented December 6, 2017, BLA Application as Early as 1Q18 ACCESSWIRE
Nov-27-17 08:05AM  Analysis: Positioning to Benefit within Aradigm, General Motors, AT&T, Denbury Resources, Novavax, and Immunomedics Research Highlights Growth, Revenue, and Consolidated Results GlobeNewswire
Nov-20-17 07:40AM  Featured Company News - Biohaven Pharma Completed Enrollment in First of Two Pivotal Phase-3 Clinical Trials of Rimegepant for Acute Treatment of Migraine ACCESSWIRE
Nov-16-17 08:43AM  Options Traders Expect Huge Moves in Immunomedics (IMMU) Stock Zacks +8.11%
Nov-15-17 08:38AM  Immunomedics (IMMU) Jumps: Stock Rises 5.4% Zacks +5.31%
Nov-14-17 04:07PM  Edited Transcript of IMMU earnings conference call or presentation 9-Nov-17 10:00pm GMT Thomson Reuters StreetEvents +5.40%
12:44PM  Cowen Bets on Immunomedics Securing Accelerated Approval Even After Decreased Overall Survival Seen in IMMU-132 Abstract SmarterAnalyst
Nov-13-17 04:30PM  Why Sears Holdings, Immunomedics, and J.C. Penney Slumped Today Motley Fool -19.35%
09:30AM  Immunomedics Announces Presentations and Investor Event at the 2017 San Antonio Breast Cancer Symposium GlobeNewswire
07:24AM  Immunomedics, Inc. breached its 50 day moving average in a Bullish Manner : IMMU-US : November 13, 2017 Capital Cube
Nov-10-17 03:02PM  Why Immunomedics, Inc. Jumped Higher Today Motley Fool +18.77%
08:20AM  Todays Research Reports on Trending Tickers: Endo International and Immunomedics ACCESSWIRE
Nov-09-17 05:21PM  Immunomedics reports 1Q loss Associated Press
04:10PM  Immunomedics Announces First Quarter Fiscal 2018 Results and Provides Corporate Update GlobeNewswire
04:05PM  Immunomedics Appoints Michael Pehl President and Chief Executive Officer to Lead Next Phase of Transformative Growth GlobeNewswire
01:00PM  Immunomedics, Inc. to Host Earnings Call ACCESSWIRE
Nov-02-17 08:00AM  Immunomedics to Report First Quarter Fiscal 2018 Results and Host Conference Call and Webcast on November 9, 2017 GlobeNewswire +6.82%
Oct-31-17 12:13PM  Immunomedics, Inc. Value Analysis (NASDAQ:IMMU) : October 31, 2017 Capital Cube -5.13%
11:42AM  ETFs with exposure to Immunomedics, Inc. : October 31, 2017 Capital Cube
Oct-30-17 08:11AM  Immunomedics, Inc. breached its 50 day moving average in a Bullish Manner : IMMU-US : October 30, 2017 Capital Cube
Oct-27-17 09:35AM  Versartis Drops on Q3 Numbers, Hires Adviser -- Biotech Movers TheStreet.com +6.18%
Oct-23-17 08:37AM  Are Options Traders Betting on a Big Move in Immunomedics (IMMU) Stock? Zacks
Oct-05-17 12:21PM  Edited Transcript of IMMU earnings conference call or presentation 16-Aug-17 9:00pm GMT Thomson Reuters StreetEvents -8.50%
Oct-03-17 11:19AM  ETFs with exposure to Immunomedics, Inc. : October 3, 2017 Capital Cube
Sep-15-17 04:30PM  Why Carnival, Immunomedics, and Fitbit Slumped Today Motley Fool
08:00AM  Immunomedics Announces Agreements to Exchange Approximately $80.0 Million of Its 4.75% Convertible Senior Notes Due 2020 for Common Stock GlobeNewswire
Sep-11-17 09:00AM  Are Options Traders Betting on a Big Move in Immunomedics (IMMU) Stock? Zacks +5.17%
07:00AM  Immunomedics Presents Interim Phase 2 Results With Sacituzumab Govitecan (IMMU-132) in Patients With Pretreated Metastatic Urothelial Cancer GlobeNewswire
Aug-30-17 08:00AM  Immunomedics to Participate in Upcoming Investor Conferences GlobeNewswire
Aug-28-17 05:33PM  ETFs with exposure to Immunomedics, Inc. : August 28, 2017 Capital Cube +14.07%
03:30PM  Here's Why Immunomedics Rose as Much as 14.2% Today Motley Fool
Aug-24-17 12:51PM  Harry Boxer: These three biotech stocks are breaking out MarketWatch +9.88%
Immunomedics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of monoclonal antibody-based products for the targeted treatment of cancer, autoimmune disorders, and other diseases. The company engages in developing antibody-drug conjugate (ADC) products comprising IMMU-132, an ADC that contains SN-38, which is in Phase II trials used for the treatment of patients with metastatic triple-negative breast cancer, and small-cell and non-small-cell lung cancers; IMMU-130, an anti-CEACAN5-SN-38 ADC that is in Phase II trials for the treatment of solid tumors and metastatic colorectal cancer; and IMMU-140 that targets HLA-DR for the potential treatment of liquid cancers. It also develops products for the treatment of cancer and autoimmune diseases, including epratuzumab, anti-CD22 antibody; veltuzumab, anti-CD20 antibody; milatuzumab, anti-CD74 antibody; and IMMU-114, a humanized anti-HLA-DR antibody. The company also provides LeukoScan, a diagnostic imaging product to determine the location and extent of infection/inflammation in bone. In addition, it offers other product candidates for the treatment of solid tumors and hematologic malignancies, as well as other diseases, which are in various stages of clinical and pre-clinical development. The company has a research collaboration with The Bayer Group to study epratuzumab as a thorium-227-labeled antibody; and a collaboration agreement with University of Wisconsin Carbone Cancer Center to expand IMMU-132 into prostate cancer. Immunomedics, Inc. was founded in 1982 and is headquartered in Morris Plains, New Jersey.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
venBio Select Advisor LLCDirectorJun 15Buy24.00575,00013,800,00017,514,461Jun 15 02:02 PM
venBio Select Advisor LLCDirectorJun 15Buy23.39200,0004,678,00017,714,461Jun 19 04:05 PM
GOLDENBERG DAVID MDirectorMar 07Sale17.6840,000707,0005,613,252Mar 12 08:32 PM
GOLDENBERG DAVID MDirectorMar 07Sale17.5020,000350,0001,774,285Mar 12 08:32 PM
GOLDENBERG DAVID MDirectorMar 05Sale17.2440,000689,4005,653,252Mar 12 08:32 PM
GOLDENBERG DAVID MDirectorFeb 28Sale17.0917,729302,9895,693,252Mar 12 08:32 PM
MARKISON BRIAN ADirectorNov 20Option Exercise3.1615,00047,40099,178Nov 21 05:00 PM
MARKISON BRIAN ADirectorNov 20Sale11.898,39099,72490,788Nov 21 05:00 PM
venBio Select Advisor LLCDirectorNov 15Buy10.97175,0001,919,75016,064,461Nov 16 11:47 AM
Aghazadeh BehzadDirectorNov 15Buy10.97175,0001,919,75016,064,461Nov 15 05:48 PM
venBio Select Advisor LLCDirectorNov 14Buy10.391,150,00011,948,50015,889,461Nov 16 11:47 AM
Aghazadeh BehzadDirectorNov 14Buy10.391,150,00011,948,50015,889,461Nov 15 05:48 PM
GOLDENBERG CYNTHIA LDirectorSep 01Sale12.9010,000129,000778,219Sep 05 07:10 PM
GOLDENBERG DAVID MSee RemarksSep 01Sale12.9010,000129,0003,395,578Sep 05 07:10 PM
GOLDENBERG CYNTHIA LDirectorAug 31Sale12.3810,000123,750788,219Sep 05 07:10 PM
GOLDENBERG DAVID MSee RemarksAug 31Sale12.3810,000123,7503,405,578Sep 05 07:10 PM
GOLDENBERG CYNTHIA LDirectorAug 28Sale11.5215,000172,841798,219Aug 28 08:54 PM
GOLDENBERG DAVID MSee RemarksAug 28Sale11.5610,000115,5913,415,578Aug 28 08:54 PM
GOLDENBERG CYNTHIA LDirectorAug 24Sale10.2425,000256,105813,219Aug 28 08:54 PM
GOLDENBERG CYNTHIA LDirectorAug 23Sale9.5010,00095,000838,219Aug 23 09:00 PM
GOLDENBERG DAVID MSee RemarksAug 23Sale9.5010,00095,0003,455,578Aug 23 09:00 PM
GOLDENBERG CYNTHIA LDirectorAug 22Sale9.5010,00095,000848,219Aug 23 09:00 PM
GOLDENBERG DAVID MSee RemarksAug 22Sale9.5010,00095,0003,465,578Aug 23 09:00 PM
GOLDENBERG CYNTHIA LDirectorAug 21Sale8.9720,000179,426858,219Aug 23 09:00 PM
GOLDENBERG DAVID MSee RemarksAug 21Sale8.9720,000179,4263,475,578Aug 23 09:00 PM
ASFI Asta Funding, Inc. daily Stock Chart
ASFI [NASD]
Asta Funding, Inc.
Index- P/E- EPS (ttm)-0.07 Insider Own70.98% Shs Outstand6.62M Perf Week2.94%
Market Cap23.18M Forward P/E- EPS next Y- Insider Trans0.00% Shs Float1.31M Perf Month-12.50%
Income- PEG- EPS next Q- Inst Own16.65% Short Float0.40% Perf Quarter2.94%
Sales48.03M P/S0.48 EPS this Y- Inst Trans- Short Ratio0.91 Perf Half Y3.70%
Book/sh18.45 P/B0.19 EPS next Y- ROA- Target Price8.00 Perf Year-9.80%
Cash/sh- P/C- EPS next 5Y10.00% ROE- 52W Range3.15 - 5.30 Perf YTD1.63%
Dividend- P/FCF- EPS past 5Y-19.53% ROI- 52W High-33.96% Beta-
Dividend %- Quick Ratio- Sales past 5Y- Gross Margin- 52W Low11.27% ATR0.13
Employees188 Current Ratio- Sales Q/Q-21.80% Oper. Margin- RSI (14)47.21 Volatility2.35% 3.32%
OptionableYes Debt/Eq- EPS Q/Q-42.70% Profit Margin- Rel Volume0.10 Prev Close3.50
ShortableYes LT Debt/Eq- Earnings- Payout- Avg Volume5.81K Price3.50
Recom- SMA20-0.43% SMA50-2.51% SMA200-4.50% Volume594 Change0.00%
Feb-24-09Upgrade Keefe Bruyette Mkt Perform → Outperform $16
Jun-02-08Reiterated Kaufman Bros Hold $5 → $9
May-30-08Initiated Keefe Bruyette Mkt Perform $8
May-05-08Reiterated Kaufman Bros Hold $25 → $15
Feb-12-08Reiterated Kaufman Bros Hold $30 → $25
Jan-09-08Reiterated Kaufman Bros Hold $40 → $30
Dec-18-07Downgrade Kaufman Bros Buy → Hold $55 → $40
Jun-29-07Initiated Kaufman Bros Buy $55
May-18-18 04:10PM  Asta Funding, Inc. Announces Receipt of Nasdaq Non-Compliance Letter GlobeNewswire
Apr-20-18 08:34PM  What Are The Drivers Of Asta Funding Incs (NASDAQ:ASFI) Risks? Simply Wall St.
Apr-05-18 12:49AM  Corrections & Amplifications The Wall Street Journal -5.48%
Apr-04-18 02:47PM  [$$] Debt-Collection Firm Settles Class-Action Lawsuit The Wall Street Journal
Apr-01-18 11:37PM  [$$] Debt-Collection Firm Settles Class-Action Lawsuit The Wall Street Journal
Mar-20-18 07:10AM  Who Are The Largest Shareholders In Asta Funding Inc (NASDAQ:ASFI)? Simply Wall St.
Mar-12-18 08:30AM  Does Asta Funding Incs (NASDAQ:ASFI) -116.35% Earnings Drop Reflect A Longer Term Trend? Simply Wall St.
Feb-22-18 03:00PM  Asta Funding, Inc. Announces Receipt of Nasdaq Non-Compliance Letter GlobeNewswire
Feb-05-18 04:45PM  Asta Funding, Inc. Announces $5.30 Per Share Special Cash Dividend GlobeNewswire
Jan-19-18 12:15PM  Asta Funding, Inc. Announces Receipt of Nasdaq Non-Compliance Letter GlobeNewswire
Jan-18-18 05:12PM  Asta Funding, Inc. Announces Decision to Restate 2014, 2015 and 2016 Financial Statements GlobeNewswire
Dec-20-17 06:05PM  How Does Asta Funding Inc (NASDAQ:ASFI)s Prospect Stack Up Next To Its Financial Peers? Simply Wall St.
11:33AM  ETFs with exposure to Asta Funding, Inc. : December 20, 2017 Capital Cube
Dec-19-17 02:55PM  Is Asta Funding Incs (NASDAQ:ASFI) CEO Salary Justified? Simply Wall St.
Dec-12-17 06:04AM  Who Are The Largest Shareholders In Asta Funding Inc (undefined:ASFI)? Simply Wall St.
Dec-06-17 04:41PM  Want To Invest In Asta Funding Inc (ASFI)? Heres How It Performed Lately Simply Wall St.
Dec-05-17 12:20PM  ETFs with exposure to Asta Funding, Inc. : December 5, 2017 Capital Cube
Oct-18-17 09:36AM  ETFs with exposure to Asta Funding, Inc. : October 18, 2017 Capital Cube
Oct-09-17 03:19PM  Why Asta Funding Inc (ASFI) May Not Be As Efficient As Its Industry Simply Wall St.
Sep-28-17 10:09AM  ETFs with exposure to Asta Funding, Inc. : September 28, 2017 Capital Cube
Sep-21-17 12:01PM  Asta Funding, Inc. :ASFI-US: Earnings Analysis: Q3, 2017 By the Numbers : September 21, 2017 Capital Cube
Aug-15-17 04:11PM  Edited Transcript of ASFI earnings conference call or presentation 9-Aug-17 1:30pm GMT Thomson Reuters StreetEvents
Aug-09-17 11:39PM  Asta Funding posts 3Q profit Associated Press
08:30AM  Asta Funding Announces Results for The Third Quarter Ended June 30, 2017 GlobeNewswire
Jul-13-17 03:29PM  ETFs with exposure to Asta Funding, Inc. : July 13, 2017 Capital Cube
Jun-19-17 02:56PM  ETFs with exposure to Asta Funding, Inc. : June 19, 2017 Capital Cube
Jun-16-17 11:35AM  Asta Funding, Inc. :ASFI-US: Earnings Analysis: Q2, 2017 By the Numbers : June 16, 2017 Capital Cube +8.18%
08:15AM  Featured Company News - WEX Announces an Agreement with GasBuddy; Set to Expand the Retail Gasoline Accesswire
Jun-09-17 02:15PM  Edited Transcript of ASFI earnings conference call or presentation 26-May-17 1:30pm GMT Thomson Reuters StreetEvents
May-30-17 04:00PM  Asta Funding, Inc. Announces Receipt of Nasdaq Compliance Letter GlobeNewswire
May-26-17 08:12AM  Asta Funding reports 2Q loss Associated Press
08:00AM  Asta Funding Announces Results for the Second Quarter Ended March 31, 2017 GlobeNewswire
May-23-17 04:05PM  Asta Funding, Inc. Announces Receipt of Nasdaq Non-Compliance Letter GlobeNewswire
May-15-17 08:00PM  Asta Funding, Inc. Announces Decision to Restate First Quarter 2017 GlobeNewswire
Apr-10-17 04:56PM  CBC Settlement Funding Completes BBRVII 2017--Private Placement Note Offering GlobeNewswire -5.26%
Mar-16-17 05:23PM  ASTA FUNDING INC Files SEC form 8-K, Changes in Registrant's Certifying Accountant
Mar-14-17 12:06PM  Asta Funding, Inc. :ASFI-US: Earnings Analysis: Q1, 2017 By the Numbers : March 14, 2017 Capital Cube
12:06PM  Asta Funding, Inc. :ASFI-US: Earnings Analysis: Q1, 2017 By the Numbers : March 14, 2017
Feb-22-17 04:05PM  Asta Funding, Inc. Announces Final Results of its Tender Offer GlobeNewswire
Feb-16-17 04:05PM  Asta Funding, Inc. Announces Preliminary Results of its Tender Offer GlobeNewswire
Feb-15-17 01:04PM  ASTA FUNDING INC Financials
Feb-09-17 09:00PM  Edited Transcript of ASFI earnings conference call or presentation 9-Feb-17 2:00pm GMT Thomson Reuters StreetEvents
09:05AM  ASTA FUNDING INC Files SEC form 8-K, Results of Operations and Financial Condition
08:38AM  Asta Funding reports 1Q loss Associated Press
08:00AM  Asta Funding Announces Results for The First Quarter Ended December 31, 2016 GlobeNewswire
Feb-02-17 08:41AM  ASTA FUNDING INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits
08:30AM  Asta Funding, Inc. Extends Tender Offer Until 11:59 p.m., February 15, 2017 GlobeNewswire
Jan-19-17 08:42AM  ASTA FUNDING INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits
08:15AM  Asta Funding, Inc. Announces Commencement of Tender Offer to Purchase Up to 5,314,009 Shares of its Common Stock GlobeNewswire
Jan-09-17 09:27AM  ASTA FUNDING INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Amendments to Articles of Inc. or By
09:15AM  Asta Funding Reaches Agreement with Mangrove Partners GlobeNewswire
Dec-22-16 12:51PM  ETFs with exposure to Asta Funding, Inc. : December 22, 2016 Capital Cube
12:51PM  ETFs with exposure to Asta Funding, Inc. : December 22, 2016
Dec-16-16 08:11AM  Asta Funding, Inc. :ASFI-US: Earnings Analysis: 2016 By the Numbers : December 16, 2016 Capital Cube
08:11AM  Asta Funding, Inc. :ASFI-US: Earnings Analysis: 2016 By the Numbers : December 16, 2016
Dec-14-16 12:19PM  Edited Transcript of ASFI earnings conference call or presentation 14-Dec-16 3:00pm GMT Thomson Reuters StreetEvents
10:01AM  ASTA FUNDING INC Files SEC form 8-K, Results of Operations and Financial Condition
09:00AM  Asta Funding Announces Results for The Fourth Quarter and Fiscal Year Ended September 30, 2016 GlobeNewswire
Nov-28-16 04:07PM  ASTA FUNDING INC Files SEC form 8-K, Termination of a Material Definitive Agreement
Nov-15-16 04:17PM  ASTA FUNDING INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Change in Directors or Principal Off
04:05PM  Asta Funding Announces the Formation of a Wholly Owned Subsidiary to Expand its Personal Injury Claims Funding Business GlobeNewswire
Nov-01-16 11:49AM  ETFs with exposure to Asta Funding, Inc. : November 1, 2016 Capital Cube
11:49AM  ETFs with exposure to Asta Funding, Inc. : November 1, 2016
Oct-05-16 10:05AM  ETFs with exposure to Asta Funding, Inc. : October 5, 2016 -5.44%
Sep-06-16 09:54AM  ETFs with exposure to Asta Funding, Inc. : September 6, 2016
Aug-18-16 11:32AM  Asta Funding, Inc. :ASFI-US: Earnings Analysis: Q3, 2016 By the Numbers : August 18, 2016
Aug-17-16 12:03PM  ASTA FUNDING INC Files SEC form 8-K, Change in Directors or Principal Officers, Regulation FD Disclosure
08:00AM  Asta Funding Appoints Mark Levenfus as New member to its Board GlobeNewswire
Aug-09-16 02:34PM  Edited Transcript of ASFI earnings conference call or presentation 9-Aug-16 2:00pm GMT
12:18PM  ASTA FUNDING INC Files SEC form 8-K, Results of Operations and Financial Condition
09:26AM  Asta Funding posts 3Q profit
07:45AM  Asta Funding Announces Results for Three and Nine Months Ended June 30, 2016 GlobeNewswire
07:07AM  Q3 2016 Asta Funding Inc Earnings Release - Before Market Open
Aug-04-16 08:00AM  Asta Funding, Inc. to Report Financial Results for the Three and Nine Months Ended June 30, 2016 GlobeNewswire
Jul-11-16 05:31PM  ASTA FUNDING INC Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits
05:12PM  CBC Settlement Funding Completes BBRVI 2016-A Private Placement Note Offering GlobeNewswire
May-26-16 07:11PM  ETFs with exposure to Asta Funding, Inc. : May 26, 2016
05:12PM  ASTA FUNDING INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements and Exhibits
May-19-16 05:23PM  ASTA FUNDING INC Files SEC form 8-K, Other Events
May-18-16 11:20AM  Asta Funding, Inc. :ASFI-US: Earnings Analysis: Q2, 2016 By the Numbers
May-17-16 11:31AM  Asta Funding Inc (ASFI): Mangrove Partners Ups Its Stake and Demands Representation on the Board at Insider Monkey
May-13-16 02:01PM  Edited Transcript of ASFI earnings conference call or presentation 13-May-16 1:00pm GMT
09:00AM  Asta Funding, Inc. Announces Final Results of Its Modified Dutch Auction Tender Offer GlobeNewswire
May-10-16 06:05PM  ASTA FUNDING INC Files SEC form 10-Q, Quarterly Report
04:19PM  Asta Funding reports 2Q loss
04:00PM  Asta Funding, Inc. Announces Financial Results for the Second Quarter and First Six Months of Fiscal 2016 GlobeNewswire
May-03-16 04:45PM  Asta Funding, Inc. Announces Clarifying Amendment of Its Tender Offer to Purchase Up to 3,000,000 Shares of Its Common Stock GlobeNewswire
Apr-21-16 02:31PM  Asta Funding Reiterates Its Rejection Of Unsolicited Tender Offer Benzinga
12:50PM  Asta Funding, Inc.s Board of Directors Reaffirms Recommendation that Shareholders Reject Amended Unsolicited Tender Offer GlobeNewswire
Apr-15-16 02:55PM  Mangrove Announces Increase of Purchase Price and Extension of Expiration Date of Tender Offer of Asta Funding, Inc. PR Newswire
Apr-11-16 03:19PM  Asta Funding, Inc. Announces Commencement of Tender Offer to Purchase Up to 3,000,000 Shares of Its Common Stock GlobeNewswire
Apr-06-16 01:19PM  Mangrove Partners Continues Activist Battle Against Asta Funding
Apr-05-16 05:56PM  Mangrove Announces Waiver of Condition of Tender Offer of Asta Funding, Inc. PR Newswire
Apr-04-16 04:12PM  Asta Funding, Inc.: Strong price momentum but will it sustain?
Mar-31-16 10:00PM  Asta Funding, Inc.s Board of Directors Rejects Unsolicited Tender Offer GlobeNewswire
04:16PM  ASTA FUNDING INC Files SEC form 8-K, Entry into a Material Definitive Agreement
Mar-17-16 01:01PM  ASTA FUNDING INC Files SEC form 8-K, Other Events
12:38PM  Asta Funding, Inc. Extends the Rule 10b5-1 Plan in Conjunction With Share Repurchase Program GlobeNewswire
Mar-15-16 05:40PM  ASTA FUNDING INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Change in Directors or Principal Off
09:25AM  Mangrove Announces Intention to Commence Tender Offer for up to 3,000,000 Shares of Common Stock of Asta Funding, Inc. PR Newswire
Asta Funding, Inc., together with its subsidiaries, engages in the consumer receivable business in the United States. The company operates through four segments: Consumer Receivables, Personal Injury Claims, Structured Settlements, and GAR Disability Advocacy. The Consumer Receivables segment involved in the purchase, management, and servicing distressed consumer receivables, including charged-off receivables consisting of accounts that have been written-off by the originators and might have been previously serviced by collection agencies; semi-performing receivables, including accounts where the debtor is currently making partial or irregular monthly payments, but the accounts might have been written-off by the originators; and performing receivables comprising accounts where the debtor is making regular monthly payments that might or might not have been delinquent in the past. Its distressed consumer receivables include MasterCard, Visa, and other credit card accounts, which were charged-off by the issuers or providers for non-payment. The Personal Injury Claims segment invests in funding personal injury claims. The Structured Settlements segment purchases periodic structured settlements and annuity policies from individuals in exchange for a lump sum payment. The GAR Disability Advocacy segment obtains and represents individuals in their claims for social security disability and supplemental security income benefits from the social security administration. Asta Funding, Inc. was founded in 1994 and is headquartered in Englewood Cliffs, New Jersey.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Berman SethSecretary & General CounselFeb 13Option Exercise2.952,5007,3752,500Feb 15 12:24 PM
SKY Skyline Corporation daily Stock Chart
SKY [NYSE]
Skyline Corporation
Index- P/E33.85 EPS (ttm)0.94 Insider Own32.50% Shs Outstand8.38M Perf Week-4.66%
Market Cap265.48M Forward P/E42.81 EPS next Y0.74 Insider Trans0.00% Shs Float4.24M Perf Month-3.80%
Income8.10M PEG1.13 EPS next Q0.15 Inst Own59.10% Short Float19.18% Perf Quarter27.05%
Sales233.70M P/S1.14 EPS this Y-99.70% Inst Trans0.63% Short Ratio7.35 Perf Half Y59.59%
Book/sh3.73 P/B8.49 EPS next Y-12.94% ROA14.10% Target Price33.50 Perf Year450.52%
Cash/sh1.68 P/C18.83 EPS next 5Y30.00% ROE28.50% 52W Range5.27 - 35.65 Perf YTD156.96%
Dividend- P/FCF28.55 EPS past 5Y14.90% ROI1.20% 52W High-11.14% Beta2.04
Dividend %- Quick Ratio1.50 Sales past 5Y5.30% Gross Margin13.40% 52W Low501.45% ATR1.47
Employees1200 Current Ratio2.20 Sales Q/Q12.40% Oper. Margin3.60% RSI (14)46.58 Volatility3.35% 4.32%
OptionableNo Debt/Eq0.00 EPS Q/Q148.40% Profit Margin3.50% Rel Volume0.76 Prev Close31.40
ShortableYes LT Debt/Eq0.00 EarningsAug 10 AMC Payout0.00% Avg Volume110.71K Price31.68
Recom2.30 SMA20-4.84% SMA501.96% SMA20052.46% Volume84,849 Change0.89%
Jul-03-18 06:05PM  Skyline Champion Corporation to Participate in CJS Securities 18th Annual New Ideas Summer Conference Business Wire
Jun-22-18 09:04AM  Is It Time To Sell Skyline Corporation (NYSEMKT:SKY) Based Off Its PE Ratio? Simply Wall St.
Jun-12-18 03:08PM  Does Skyline Champion Corporations (NYSE:SKY) PE Ratio Warrant A Sell? Simply Wall St.
Jun-04-18 07:00AM  Skyline and Champion Home Builders Announce Closing of Business Combination to Create Skyline Champion Corporation Business Wire
May-28-18 07:13AM  What You Must Know About Skyline Corporations (NYSEMKT:SKY) ROE Simply Wall St.
May-17-18 03:30PM  Skyline Announces Intent To List On The New York Stock Exchange In Connection With Exchange Transaction With Champion Enterprises Holdings, LLC PR Newswire
May-15-18 04:35PM  Skyline Declares Special Company Dividend In Connection With Exchange Transaction PR Newswire
May-02-18 05:11PM  INVESTOR ALERT: Levi & Korsinsky, LLP Reminds Investors of an Investigation of Skyline Corporation Business Wire
Apr-27-18 03:15PM  READ NOW: Monteverde & Associates PC is Investigating Upcoming Skyline Corporation Vote Set for May 29, 2018 - SKY ACCESSWIRE
Apr-12-18 05:30PM  Skyline Reports Third Quarter And First Nine Months Results PR Newswire
05:19PM  Skyline: Fiscal 3Q Earnings Snapshot Associated Press
Apr-10-18 04:51PM  SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation of Skyline Corporation Business Wire
Mar-22-18 09:23AM  Skyline AI raises $3M from Sequoia Capital to help real estate investors make better decisions TechCrunch
Mar-20-18 04:18AM  Was Skyline Investment SA.s (WSE:SKL) Earnings Growth Better Than The Industrys? Simply Wall St.
Mar-07-18 05:27PM  Shareholder Alert: Monteverde & Associates PC Announces An Investigation Of Skyline Corporation. - SKY PR Newswire +6.19%
Mar-02-18 06:00AM  [$$] Lounge in style and live in splendid isolation Financial Times
Jan-23-18 07:00PM  Skyline and Champion Home Builders to Host Conference Call on Proposed Business Combination on Thursday, January 25 PR Newswire
Jan-11-18 05:59PM  Skyline posts 2Q profit Associated Press
05:30PM  Skyline Reports Second Quarter And First Half Results PR Newswire
Jan-09-18 07:20AM  Wired News Skyline and Champion Home Builders Announce Agreement to Merge Operations ACCESSWIRE
Jan-05-18 04:47PM  2 Stocks Jump on Friday GuruFocus.com +48.09%
12:00PM  [$$] PE-Backed Champion Enterprises and Skyline to Combine Operations The Wall Street Journal
09:00AM  Skyline and Champion Home Builders Announce Agreement on Business Combination to Create the Nation's Largest Publicly Traded Factory-Built Housing Company PR Newswire
Dec-27-17 11:49AM  ETFs with exposure to Skyline Corp. : December 27, 2017 Capital Cube
Dec-11-17 02:09PM  ETFs with exposure to Skyline Corp. : December 11, 2017 Capital Cube
Nov-29-17 12:20PM  ETFs with exposure to Skyline Corp. : November 29, 2017 Capital Cube
Nov-17-17 06:01AM  [$$] Drones will reshape how we build our cities Financial Times
Nov-14-17 02:50PM  ETFs with exposure to Skyline Corp. : November 14, 2017 Capital Cube
Nov-03-17 12:33PM  ETFs with exposure to Skyline Corp. : November 3, 2017 Capital Cube
Oct-23-17 11:03AM  ETFs with exposure to Skyline Corp. : October 23, 2017 Capital Cube +7.80%
Oct-10-17 11:49AM  ETFs with exposure to Skyline Corp. : October 10, 2017 Capital Cube -6.85%
Oct-09-17 10:08AM  Skyline Corp. :SKY-US: Earnings Analysis: Q1, 2018 By the Numbers : October 9, 2017 Capital Cube
Oct-06-17 05:40PM  Skyline posts 1Q profit Associated Press +6.09%
05:30PM  Skyline Reports First Quarter Results PR Newswire
Sep-07-17 01:54PM  ETFs with exposure to Skyline Corp. : September 7, 2017 Capital Cube -7.60%
Aug-24-17 04:07PM  ETFs with exposure to Skyline Corp. : August 24, 2017 Capital Cube
Aug-15-17 10:48AM  Skyline Corp. :SKY-US: Earnings Analysis: Q4, 2017 By the Numbers : August 15, 2017 Capital Cube
Aug-11-17 10:52PM  Skyline posts 4Q profit Associated Press
05:30PM  Skyline Reports Fourth Quarter And Year-End Results PR Newswire
Aug-09-17 04:03PM  ETFs with exposure to Skyline Corp. : August 9, 2017 Capital Cube
Jul-26-17 01:33PM  Skyline Corp.: Strong price momentum but will it sustain? Capital Cube +16.30%
Jun-14-17 05:30PM  Skyline Corporation Announces Director Retirements PR Newswire
Jun-02-17 06:00PM  United Way of Elkhart County Honors Skyline Corporation PR Newswire +5.42%
May-05-17 02:34PM  Skyline Corp.: Strong price momentum but will it sustain? Capital Cube +6.06%
May-01-17 04:25PM  ETFs with exposure to Skyline Corp. : May 1, 2017 Capital Cube
Apr-19-17 02:36PM  ETFs with exposure to Skyline Corp. : April 19, 2017 Capital Cube +5.58%
Apr-17-17 09:21AM  Skyline Corp. :SKY-US: Earnings Analysis: Q3, 2017 By the Numbers : April 17, 2017 Capital Cube -27.81%
Apr-14-17 05:30PM  Skyline Reports Third Quarter And First Nine Months Results PR Newswire
Mar-07-17 04:56PM  SKYLINE CORP Files SEC form 8-K, Costs Associated with Exit or Disposal Activities -7.81%
Mar-02-17 04:58PM  SKYLINE CORP Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements and Exhibits
Mar-01-17 05:30PM  Skyline Corporation Names Jeff Newport Chief Operating Officer PR Newswire
05:09PM  SKYLINE CORP Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and Exhibits
Feb-21-17 05:03PM  SKYLINE CORP Files SEC form 8-K, Costs Associated with Exit or Disposal Activities
Feb-10-17 05:00PM  Skyline "Brings America Home" at 2017 Louisville Manufactured Housing Show PR Newswire
Jan-25-17 05:00PM  RV Business Top Debuts for 2017 - Shore Park by Skyline, model 1969CTA PR Newswire
Jan-19-17 01:57PM  ETFs with exposure to Skyline Corp. : January 19, 2017 Capital Cube
01:57PM  ETFs with exposure to Skyline Corp. : January 19, 2017
Jan-18-17 01:04PM  SKYLINE CORP Financials
Jan-16-17 09:09AM  Skyline Corp. :SKY-US: Earnings Analysis: Q2, 2017 By the Numbers : January 16, 2017 Capital Cube
09:09AM  Skyline Corp. :SKY-US: Earnings Analysis: Q2, 2017 By the Numbers : January 16, 2017
Jan-13-17 05:11PM  SKYLINE CORP Files SEC form 8-K, Change in Directors or Principal Officers -7.51%
Jan-12-17 05:30PM  Skyline Reports Second Quarter And First Half Results PR Newswire
05:08PM  Skyline reports 2Q loss Associated Press
05:04PM  SKYLINE CORP Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits
Dec-15-16 10:59AM  Murdoch's Fox To Buy European Broadcaster Sky For $14.6B (FOX, SKY) Investopedia
10:59AM  Murdoch's Fox To Buy European Broadcaster Sky For $14.6B (FOX, SKY) at Investopedia
Dec-13-16 01:30PM  ETFs with exposure to Skyline Corp. : December 13, 2016 Capital Cube
01:30PM  ETFs with exposure to Skyline Corp. : December 13, 2016
Dec-09-16 12:04PM  Bank shares pull back, keeping gain on FTSE 100 in check MarketWatch
Dec-02-16 01:15PM  ETFs with exposure to Skyline Corp. : December 2, 2016
Nov-11-16 03:40PM  Skyline Corp.: Strong price momentum but will it sustain?
Oct-28-16 03:19PM  ETFs with exposure to Skyline Corp. : October 28, 2016
Oct-18-16 09:09AM  Skyline Corp. :SKY-US: Earnings Analysis: Q1, 2017 By the Numbers : October 18, 2016
Oct-13-16 05:30PM  Skyline Reports First Quarter Results PR Newswire
05:13PM  Skyline posts 1Q profit
05:04PM  SKYLINE CORP Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits
05:01PM  SKYLINE CORP Files SEC form 10-Q, Quarterly Report
Oct-12-16 05:00PM  Jeffrey Legault, P.E. is the Recipient of the Prestigious Frank Walter Standards Award from MHI PR Newswire
Oct-07-16 10:15AM  ETFs with exposure to Skyline Corp. : October 7, 2016
Sep-20-16 05:30PM  Skyline Holds Annual Shareholder Meeting PR Newswire
04:55PM  SKYLINE CORP Files SEC form 8-K, Submission of Matters to a Vote of Security Holders, Other Events
Aug-05-16 05:41PM  Skyline posts 4Q profit
05:30PM  Skyline Reports Results For Fiscal 2016 Fourth Quarter And Year End PR Newswire
05:00PM  SKYLINE CORP Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits
04:59PM  SKYLINE CORP Files SEC form 10-K, Annual Report
Aug-03-16 01:54AM  Sky Plc :SKY-GB: Earnings Analysis: For the six months ended June 30, 2016 : August 3, 2016
Jul-11-16 02:18PM  [$$] US autos: Adding new routes at Financial Times
Jul-05-16 05:30PM  Scott Parkhurst Joins Skyline Corporation As National Sales Manager PR Newswire
04:59PM  SKYLINE CORP Files SEC form 8-K, Entry into a Material Definitive Agreement, Other Events, Financial Statements and E
Jun-27-16 03:40PM  ETFs with exposure to Skyline Corp. : June 27, 2016
07:00AM  The Impact of Brexit on the Stocks We Cover at Morningstar
Jun-24-16 08:50AM  Brexit Fears Unfairly Hit European Communication Stocks at Morningstar
Jun-22-16 11:01AM  Skyline Corp. :SKY-US: Earnings Analysis: Q3, 2016 By the Numbers : June 22, 2016
May-16-16 06:02PM  SKYLINE CORP Files SEC form 8-K, Other Events
05:30PM  Skyline To Open Manufacturing Facility In Elkhart, Indiana PR Newswire
May-05-16 08:40AM  BT to invest 6 bln pounds on broadband and mobile upgrades Reuters
May-04-16 04:38PM  ETFs with exposure to Skyline Corp. : May 4, 2016
Apr-26-16 11:15AM  Easy Come, Easy Go: Skyline Sinks After Rally Fueled By Mistaken Identity at Barrons.com
11:12AM  TheStreetSweeper Goes Short Skyline: Says Investor Error Is Main Reason Shares Are Up
Apr-22-16 04:27PM  ETFs with exposure to Skyline Corp. : April 22, 2016
Skyline Champion Corporation operates as a factory-built housing company in North America. The company offers manufactured and modular homes, as well as park-models and modular buildings for the multi-family, hospitality, and senior and workforce housing sectors. It builds homes under the brand names of Skyline Homes, Champion Home Builders, Athens Park Models, Dutch Housing, Excel Homes, Homes of Merit, New Era, Redman Homes, Shore Park, Silvercrest, and Titan Homes in the United States; and Moduline and SRI Homes in western Canada. The company also operates a factory-direct retail business, Titan Factory Direct, with 21 retail locations in the southern United States. In addition, it provides transportation services to the manufactured housing and other industries. The company was founded in 2010 and is Elkhart, Indiana.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
GENDELL JEFFREY L ET AL10% OwnerJan 08Buy17.488,946156,3761,265,493Jan 09 04:30 PM
GENDELL JEFFREY L ET AL10% OwnerJan 05Buy16.8740,020675,3351,256,547Jan 09 04:30 PM
GENDELL JEFFREY L ET AL10% OwnerNov 03Buy12.454,64857,8681,216,527Nov 06 08:30 PM
GENDELL JEFFREY L ET AL10% OwnerNov 02Buy12.125,00060,6001,211,879Nov 06 08:30 PM
GENDELL JEFFREY L ET AL10% OwnerOct 19Buy11.311,42016,0601,206,879Oct 20 08:30 PM
GENDELL JEFFREY L ET AL10% OwnerOct 18Buy11.2440,000449,6001,205,459Oct 20 08:30 PM
GENDELL JEFFREY L ET AL10% OwnerOct 17Buy11.2617,900201,5541,165,459Oct 18 08:30 PM
GENDELL JEFFREY L ET AL10% OwnerOct 16Buy10.8414,520157,3971,147,559Oct 18 08:30 PM
TONTINE ASSET ASSOCIATES, L.L.10% OwnerJul 21Buy5.8552,000304,2001,133,039Jul 24 08:40 PM
TONTINE ASSET ASSOCIATES, L.L.10% OwnerJul 20Buy5.8043,000249,4001,081,039Jul 24 08:40 PM
SPPI Spectrum Pharmaceuticals, Inc. daily Stock Chart
SPPI [NASD]
Spectrum Pharmaceuticals, Inc.
Index- P/E- EPS (ttm)-0.54 Insider Own1.40% Shs Outstand104.24M Perf Week4.68%
Market Cap2.47B Forward P/E- EPS next Y-0.67 Insider Trans-42.39% Shs Float93.26M Perf Month18.80%
Income-45.20M PEG- EPS next Q-0.21 Inst Own78.90% Short Float10.80% Perf Quarter19.16%
Sales129.80M P/S19.03 EPS this Y35.80% Inst Trans0.02% Short Ratio6.57 Perf Half Y24.74%
Book/sh3.22 P/B7.36 EPS next Y17.30% ROA-18.40% Target Price29.25 Perf Year208.59%
Cash/sh2.22 P/C10.65 EPS next 5Y- ROE-28.50% 52W Range7.12 - 23.56 Perf YTD25.07%
Dividend- P/FCF- EPS past 5Y-19.40% ROI-10.50% 52W High0.59% Beta1.96
Dividend %- Quick Ratio2.90 Sales past 5Y-13.70% Gross Margin66.30% 52W Low232.95% ATR0.83
Employees215 Current Ratio3.00 Sales Q/Q4.80% Oper. Margin-77.50% RSI (14)72.61 Volatility3.89% 4.22%
OptionableYes Debt/Eq0.12 EPS Q/Q47.70% Profit Margin-64.80% Rel Volume0.63 Prev Close23.04
ShortableYes LT Debt/Eq0.00 EarningsAug 02 AMC Payout- Avg Volume1.53M Price23.70
Recom1.50 SMA2011.33% SMA5019.49% SMA20025.21% Volume972,933 Change2.86%
Dec-18-17Initiated B. Riley FBR, Inc. Buy $26
Oct-24-17Initiated Guggenheim Buy $32
Oct-19-17Reiterated H.C. Wainwright Buy $20 → $29
Oct-04-17Reiterated H.C. Wainwright Buy $14 → $20
Aug-16-17Resumed H.C. Wainwright Buy $14
Feb-10-17Resumed Jefferies Buy
Nov-05-15Reiterated RBC Capital Mkts Outperform $13 → $12
Aug-07-15Reiterated RBC Capital Mkts Outperform $12 → $13
Apr-02-15Initiated FBR Capital Outperform $9
Feb-23-15Downgrade ROTH Capital Buy → Neutral $15 → $7
Jul-15-14Upgrade R. F. Lafferty Sell → Neutral $7.50
Oct-07-13Initiated HC Wainwright Buy $15
May-29-13Initiated Burrill Institutional Research Mkt Outperform $12
Mar-13-13Reiterated RBC Capital Mkts Outperform $19 → $16
Mar-13-13Downgrade WallachBeth Buy → Sell $20 → $5.50
May-02-11Reiterated MLV Capital Buy $12.50 → $20.50
Mar-25-11Initiated RBC Capital Mkts Outperform $12
Dec-07-10Reiterated Morgan Joseph Buy $8 → $10
Jan-12-10Upgrade Morgan Joseph Hold → Buy $8
Oct-14-09Reiterated Rodman & Renshaw Mkt Outperform $10 → $8
Jul-09-18 07:20PM  Top 4 Small-Cap Stocks for 2018 Investopedia
Jun-29-18 07:00AM  Spectrum Pharmaceuticals Presents ADVANCE Phase 3 ROLONTIS® (eflapegrastim) Data at MASCC 2018 and Announces the Phase 3 RECOVER Study Met the Primary Endpoint Business Wire
Jun-27-18 12:03PM  Harry Boxers four momentum stocks breaking out MarketWatch
08:00AM  Todays Research Reports on Stocks to Watch: Spectrum Pharmaceuticals and Sophiris ACCESSWIRE
Jun-26-18 10:36AM  Here's Why Spectrum Pharmaceuticals Inc. Is Soaring Motley Fool +14.59%
09:31AM  Benzinga Pro's 5 Stocks To Watch Today Benzinga
07:15AM  Complimentary Technical Snapshots on Sorrento Therapeutics and Three More Biotech Stocks ACCESSWIRE
04:24AM  Spectrum Pharma Is Weighing a Sale Bloomberg
Jun-25-18 07:00AM  Spectrum Pharmaceuticals to Host Conference Call Highlighting ROLONTIS® (eflapegrastim) Phase 3 ADVANCE Study Data Presented at Multinational Association of Supportive Care in Cancer (MASCC) Business Wire
Jun-19-18 06:34AM  Spectrum Pharmaceuticals Sees Hammer Chart Pattern: Time to Buy? Zacks
Jun-18-18 09:01PM  Why Spectrum Pharmaceuticals Inc (NASDAQ:SPPI) Is A Financially Healthy Company Simply Wall St.
Jun-07-18 08:20AM  Today's Research Reports on Trending Tickers: Spectrum Pharmaceuticals and Tesaro ACCESSWIRE
May-30-18 07:00AM  Spectrum Pharmaceuticals to Present Corporate Update at the Jefferies 2018 Global Healthcare Conference on June 6th Business Wire
May-25-18 07:10AM  Free Research Reports on Sorrento Therapeutics and Three More Biotech Stocks ACCESSWIRE
May-17-18 01:17PM  Why Spectrum Pharmaceuticals, Inc. Is Up Big Today Motley Fool +12.11%
02:10AM  CORRECTING and REPLACING Spectrum Pharmaceuticals Announces Detailed Results from Phase 3 Study of ROLONTIS® (eflapegrastim) Published in an ASCO Abstract Business Wire
May-16-18 05:20PM  Spectrum Pharmaceuticals Announces Detailed Results from Phase 3 Study of ROLONTIS® (eflapegrastim) Published in an ASCO Abstract Business Wire
May-09-18 07:00AM  Spectrum Pharmaceuticals to Present Corporate Update at the Bank of America Merrill Lynch 2018 Health Care Conference on May 16th Business Wire
03:58AM  Edited Transcript of SPPI earnings conference call or presentation 3-May-18 8:30pm GMT Thomson Reuters StreetEvents
May-07-18 07:10AM  Blog Exposure - Spectrum Pharma Inked Licensing Agreement with The University of Texas MD Anderson Cancer Center on Certain Methods of Use of Poziotinib ACCESSWIRE
May-04-18 11:31AM  Spectrum (SPPI) Earnings and Sales Beat Estimates in Q1 Zacks
May-03-18 05:06PM  Spectrum Pharma: 1Q Earnings Snapshot Associated Press
04:00PM  Spectrum Pharmaceuticals Reports First Quarter 2018 Financial Results and Pipeline Update Business Wire
07:00AM  Spectrum Pharmaceuticals Announces Exclusive Licensing Agreement on Certain Methods of Use of Poziotinib with The University of Texas MD Anderson Cancer Center Business Wire
May-01-18 07:00AM  Spectrum Pharmaceuticals Enters into a Next-Generation Sequencing Companion Diagnostic Partnership with Thermo Fisher Scientific Business Wire
Apr-30-18 04:47PM  Can These Top-Performing Biotech Stocks Keep Climbing? Motley Fool
07:00AM  Spectrum Pharmaceuticals Announces Corporate Governance Enhancements and Board Changes Business Wire
Apr-27-18 10:40AM  Company Profile for SPECTRUM PHARMACEUTICALS Business Wire
Apr-26-18 07:00AM  Spectrum Pharmaceuticals Announces First Quarter 2018 Financial Results Teleconference and Webcast Business Wire
Apr-23-18 11:25AM  Spectrum Pharmaceuticals Announces Publication of Poziotinib Data in Nature Medicine Business Wire
Apr-17-18 02:03PM  Spectrum Pharmaceuticals Highlights Data Showing Poziotinib Overcomes De Novo Resistance of HER2 Exon 20 Insertion Mutations in NSCLC and Other Cancers at the American Association for Cancer Research (AACR) in Chicago Business Wire +7.17%
06:56AM  Heres What Happened Last Week In Biotech Market Exclusive
Apr-14-18 07:17AM  3 Biotech Stocks That Soared This Week: Are They Buys? Motley Fool
Apr-12-18 07:00AM  Wired News Spectrum Pharma Reported Update Data from MD Andersons Phase-2 Data Assessing Poziotinib in EGFR Exon 20 Mutant NSCLC Patients ACCESSWIRE
Apr-11-18 10:20AM  Biotech Stock Roundup: Spectrum Up, Incyte Down, AveXis to Merge with Novartis Zacks
10:15AM  Company News For Apr 11, 2018 Zacks
09:36AM  Spectrum Pharma Stock Up on Positive Lung Cancer Study Data Zacks
08:31AM  Implied Volatility Surging for Spectrum Pharmaceuticals (SPPI) Stock Options Zacks
08:10AM  Todays Research Reports on Stocks to Watch: Spectrum Pharmaceuticals and Tandem Diabetes Care ACCESSWIRE
Apr-10-18 04:31PM  Why Sprint, Spectrum Pharmaceuticals, and NVIDIA Jumped Today Motley Fool +41.90%
02:36PM  Benzinga's Top Analyst Calls From April 10, 2018 Benzinga
11:07AM  Why Spectrum Pharmaceuticals, Inc. Is Soaring Today Motley Fool
05:00AM  Spectrum Pharmaceuticals Announces Update of MD Andersons Phase 2 Data Studying Poziotinib in EGFR Exon 20 Mutant Non-Small Cell Lung Cancer Patients Business Wire
Apr-03-18 08:00AM  Todays Research Reports on Trending Tickers: Spectrum Pharmaceuticals and Insmed ACCESSWIRE
07:00AM  Spectrum Pharmaceuticals to Present Corporate Update at the H.C. Wainwright Global Life Sciences Conference on April 10th Business Wire
Mar-19-18 09:00AM  Is the Options Market Predicting a Spike in Spectrum Pharmaceuticals (SPPI) Stock? Zacks
Mar-07-18 06:16PM  Edited Transcript of SPPI earnings conference call or presentation 6-Mar-18 9:30pm GMT Thomson Reuters StreetEvents -14.56%
04:34PM  Why Kroger, AeroVironment, and Spectrum Pharmaceuticals Slumped Today Motley Fool
12:58PM  Here's Why Spectrum Pharmaceuticals, Inc. Is Slipping Today Motley Fool
10:35AM  Spectrum (SPPI) Q4 Loss Widens Y/Y, Sales Miss, Stock Falls Zacks
08:20AM  Todays Research Reports on Trending Tickers: ImmunoCellular Therapeutics and Spectrum Pharmaceuticals ACCESSWIRE
08:10AM  Todays Research Reports on Stocks to Watch: Spectrum Pharmaceuticals and Portola Pharmaceuticals ACCESSWIRE
07:00AM  Spectrum Pharmaceuticals to Present Corporate Update at the Cowen and Company 38th Annual Health Care Conference on March 13th Business Wire
Mar-06-18 04:47PM  Spectrum Pharma reports 4Q loss Associated Press
04:00PM  Spectrum Pharmaceuticals Reports Fourth Quarter 2017 and Full Year 2017 Financial Results and Pipeline Update Business Wire
12:15PM  Spectrum Pharmaceuticals, Inc. to Host Earnings Call ACCESSWIRE
Mar-02-18 08:53AM  Should You Sell Spectrum Pharmaceuticals (SPPI) Before Earnings? Zacks
Feb-27-18 06:00AM  Spectrum Pharmaceuticals Announces Appointment of William L. Ashton to its Board of Directors Business Wire
Feb-26-18 08:10AM  Todays Research Reports on Trending Tickers: Spectrum Pharmaceuticals and Syneos Health ACCESSWIRE
07:00AM  Spectrum Pharmaceuticals Announces Fourth Quarter and Full Year 2017 Financial Results Teleconference and Webcast Business Wire
Feb-21-18 08:00AM  New Research Coverage Highlights Acacia Research, Zebra Technologies, VSE, Spectrum Pharmaceuticals, Agenus, and Williams Companies Consolidated Revenues, Company Growth, and Expectations for 2018 GlobeNewswire
Feb-15-18 07:00AM  Spectrum Pharmaceuticals to Present Corporate Update at the 2018 RBC Capital Markets Global Healthcare Conference on February 22nd Business Wire
Feb-12-18 08:28AM  [$$] Buying United, Selling Lilly, Rambus, Tronc Barrons.com
Feb-07-18 07:00AM  Wired News Spectrum Pharmas ROLONTIS Achieved Primary Endpoint in Phase-3 ADVANCE Study ACCESSWIRE
Feb-06-18 10:10AM  Spectrum Pharma's Rolontis Positive in Pivotal Cancer Study Zacks
08:38AM  Bristol-Myers Squibb, Spectrum Just Reported Key Late Stage Data Market Exclusive
Feb-05-18 09:33AM  Benzinga Pro's 5 Stocks To Watch Today Benzinga
07:00AM  Spectrum Pharmaceuticals Announces ROLONTIS (eflapegrastim) Met the Primary Endpoint in the Phase 3 ADVANCE Study Business Wire
Jan-23-18 08:10AM  Todays Research Reports on Trending Tickers: Spectrum Pharmaceuticals and ZIOPHARM Oncology ACCESSWIRE
07:00AM  Spectrum Pharmaceuticals to Present Corporate Update at the Noble Capital Markets' Fourteenth Annual Investor Conference Business Wire
Jan-22-18 05:40PM  Spectrum Pharmaceuticals Incs (NASDAQ:SPPI) Earnings Dropped -44.12%, Did Its Industry Show Weakness Too? Simply Wall St. +9.93%
Jan-19-18 10:06AM  Spectrum Pharmaceuticals Up 134% in 6 Months: Here's Why Zacks
Jan-08-18 06:03AM  The 10 Best Stocks of 2017 Motley Fool
Dec-21-17 06:25AM  Spectrum Pharmaceuticals Inc (NASDAQ:SPPI): What Does The Future Look Like? Simply Wall St.
Dec-18-17 09:37AM  Spectrum Pharma Dismisses CEO, Makes Leadership Changes Zacks
Dec-17-17 06:59PM  Spectrum Pharmaceuticals Announces Leadership Changes Business Wire
Dec-13-17 07:00AM  Spectrum Pharmaceuticals Highlights Two Oral Presentations on FOLOTYN® (pralatrexate injection) at the 59th Annual Meeting of the American Society of Hematology (ASH) Business Wire
Dec-12-17 10:32AM  Chart in Focus: Spectrum Pharmaceuticals Financials Market Realist
09:03AM  An Overview of Spectrum Pharmaceuticals Drug Pipeline Market Realist
07:33AM  Spectrum Pharmaceuticals Product Licensing Agreements Market Realist
Dec-11-17 05:10PM  A Look at Spectrum Pharmaceuticals Recent Acquisitions Market Realist
03:36PM  Analysts Recommendations for Spectrum Pharmaceuticals Market Realist
Dec-10-17 08:44PM  18 small-cap stocks that analysts expect to rise at least 50% in 2018 MarketWatch
Dec-04-17 07:00AM  Spectrum Pharmaceuticals Highlights 15 Abstracts at the 59th Annual Meeting of the American Society of Hematology (ASH) in Atlanta, Georgia, December 9-12, 2017 Business Wire
Nov-27-17 10:06AM  Spectrum Doubles in 3 Months: What's Driving the Rally? Zacks
Nov-20-17 02:41PM  Edited Transcript of SPPI earnings conference call or presentation 2-Nov-17 8:30pm GMT Thomson Reuters StreetEvents
Nov-19-17 11:43AM  3 Biotech Stocks to Be Thankful for This Year Motley Fool
Nov-17-17 08:10AM  Todays Research Reports on Trending Tickers: Spectrum Pharmaceuticals and Myriad Genetics ACCESSWIRE -5.93%
Nov-13-17 07:50AM  Featured Company News - Infinity Shares Clinical and Translational Data from Monotherapy Dose-Escalation Component of Phase-1/1b Study for IPI-549 ACCESSWIRE
Nov-10-17 10:52AM  Ligand (LGND) Q3 Earnings & Revenues Top, 2017 View Raised Zacks
Nov-08-17 04:30PM  Stonegate Capital Partners Updates Coverage on Spectrum Pharmaceuticals, Inc. (NasdaqGS: SPPI) ACCESSWIRE
11:00AM  Why Spectrum Pharmaceuticals Stock Soared in October Motley Fool
07:00AM  Spectrum Pharmaceuticals to Present Corporate Update at the Jefferies 2017 London Healthcare Conference on November 15th Business Wire
Nov-07-17 07:40AM  Recent Analysis Shows Philip Morris, Danaher, Skechers, Sally Beauty, Spectrum Pharma, and Textron Market Influences Renewed Outlook, Key Drivers of Growth GlobeNewswire
Nov-06-17 11:59AM  Top 4 Small-Cap Stocks for 2017 Investopedia
Nov-03-17 03:22PM  Spectrum (SPPI) Earnings, Sales Beat Q3 Estimates Zacks
09:24AM  Pacific Biosciences Shares Down After Third-Quarter Results -- Biotech Movers TheStreet.com
Nov-02-17 05:33PM  Spectrum Pharma reports 3Q loss Associated Press
04:02PM  Spectrum Pharmaceuticals Reports Third Quarter 2017 Financial Results and Pipeline Update Business Wire
12:10PM  Spectrum Pharmaceuticals, Inc. to Host Earnings Call ACCESSWIRE
Spectrum Pharmaceuticals, Inc. develops and commercializes oncology and hematology drug products. The company markets six drug products, including FUSILEV for patients with metastatic colorectal cancer and rescue after high-dose methotrexate therapy in osteosarcoma, and to diminish toxicity and counteract the effects of impaired methotrexate elimination and of inadvertent overdosage of folic acid antagonists; FOLOTYN, a folate analogue metabolic inhibitor for peripheral T-cell lymphoma (PTCL); ZEVALIN injection for patients with B-cell non-Hodgkin's lymphoma; MARQIBO, a sphingomyelin/cholesterol liposome-encapsulated formulation for adult patients with Philadelphia chromosome-negative acute lymphoblastic leukemia; BELEODAQ injection for PTCL; and EVOMELA for use as a conditioning treatment prior to autologous stem cell transplant in multiple myeloma patients. It is also developing POZIOTINIB for treating breast and lung cancer; ROLONTIS for chemotherapy-induced neutropenia; and QAPZOLA for intravesical instillation in post-transurethral resection of bladder tumors in patients with non-muscle invasive bladder cancer. The company sells its drugs through group purchasing organizations, wholesalers, and directly in the United States; and through distributors in Europe. Spectrum Pharmaceuticals, Inc. has licensing and development agreement with Cell Therapeutics, Inc.; license agreement with Merck & Cie AG, Sloan-Kettering Institute, and Cydex Pharmaceuticals, Inc.; development and commercialization collaboration agreement with Allergan, Inc.; collaboration agreement with Nippon Kayaku Co., LTD.; licensing and collaboration agreement with Onxeo DK; and co-development and commercialization agreement with Hanmi Pharmaceutical Company. The company was formerly known as NeoTherapeutics, Inc. and changed its name to Spectrum Pharmaceuticals, Inc. in December 2002. Spectrum Pharmaceuticals, Inc. was founded in 1987 and is headquartered in Henderson, Nevada.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Riga Thomas JEVP, COO & CCOJun 25Sale18.762354,408240,263Jun 26 01:31 PM
LENAZ LUIGI MDDirectorMay 22Option Exercise1.4740,00058,800109,077May 22 04:52 PM
SHROTRIYA RAJESH C MDDirectorMay 17Option Exercise1.46362,926529,001563,578May 17 06:38 PM
Krassner Stuart MitchellDirectorMay 17Sale18.9421,113399,88057,944May 18 05:26 PM
Riga Thomas JEVP, COO & CCOMay 14Sale18.103,29059,552240,498May 14 04:17 PM
SHROTRIYA RAJESH C MDDirectorMay 14Sale18.3824,014441,377615,963May 14 03:59 PM
COHEN RAYMOND WDirectorMay 14Sale18.329,275169,91828,850May 15 07:03 PM
SHROTRIYA RAJESH C MDDirectorMay 11Sale17.5530,000526,500639,977May 14 03:59 PM
SHROTRIYA RAJESH C MDDirectorMay 10Sale17.1330,000513,900669,977May 14 03:59 PM
SHROTRIYA RAJESH C MDDirectorMay 09Sale16.2130,000486,300699,977May 09 04:02 PM
SHROTRIYA RAJESH C MDDirectorMay 08Sale16.1130,000483,300729,977May 09 04:02 PM
SHROTRIYA RAJESH C MDDirectorMay 07Sale15.9830,000479,400759,977May 09 04:02 PM
SHROTRIYA RAJESH C MDDirectorMay 04Sale16.7930,000503,700789,977May 04 03:37 PM
SHROTRIYA RAJESH C MDDirectorMay 03Sale16.0130,000480,300819,977May 04 03:37 PM
SHROTRIYA RAJESH C MDDirectorMay 02Sale16.0430,000481,200849,977May 04 03:37 PM
SHROTRIYA RAJESH C MDDirectorMay 01Sale15.7730,000473,100879,977May 01 05:55 PM
SHROTRIYA RAJESH C MDDirectorApr 30Sale16.3630,000490,800909,977May 01 05:55 PM
SHROTRIYA RAJESH C MDDirectorApr 27Sale17.1730,000515,100939,977May 01 05:55 PM
SHROTRIYA RAJESH C MDDirectorApr 26Sale17.2630,000517,800969,977Apr 26 06:39 PM
SHROTRIYA RAJESH C MDDirectorApr 25Sale17.2630,000517,800999,977Apr 26 06:39 PM
SHROTRIYA RAJESH C MDDirectorApr 24Sale18.1130,000543,3001,029,977Apr 26 06:39 PM
SHROTRIYA RAJESH C MDDirectorApr 23Sale18.3730,000551,1001,059,977Apr 23 09:53 PM
SHROTRIYA RAJESH C MDDirectorApr 20Sale18.6730,000560,1001,089,977Apr 23 09:53 PM
SHROTRIYA RAJESH C MDDirectorApr 19Sale19.1830,000575,4001,119,977Apr 23 09:53 PM
SHROTRIYA RAJESH C MDDirectorApr 18Sale19.7130,000591,3001,149,977Apr 18 04:38 PM
Turgeon Joseph W.CEO & PresidentApr 17Sale19.0011,565219,751316,509Apr 18 04:40 PM
SHROTRIYA RAJESH C MDDirectorApr 17Sale18.5630,000556,8001,179,977Apr 18 04:38 PM
Riga Thomas JEVP, COO & CCOApr 17Sale19.071,84035,083243,854Apr 17 07:04 PM
SHROTRIYA RAJESH C MDDirectorApr 16Sale18.7230,000561,6001,209,977Apr 18 04:38 PM
Riga Thomas JEVP, COO & CCOApr 16Sale18.603,90072,521254,694Apr 17 07:04 PM
SHROTRIYA RAJESH C MDDirectorApr 13Sale19.9330,000597,9001,239,977Apr 13 05:07 PM
SHROTRIYA RAJESH C MDDirectorApr 12Sale20.7230,000621,6001,269,977Apr 13 05:07 PM
SHROTRIYA RAJESH C MDDirectorApr 11Sale20.3030,000609,0001,299,977Apr 13 05:07 PM
SHROTRIYA RAJESH C MDDirectorApr 10Sale17.7430,000532,2001,329,977Apr 10 08:41 PM
SHROTRIYA RAJESH C MDDirectorApr 09Sale15.0112,300184,6231,359,977Apr 10 08:41 PM
SHROTRIYA RAJESH C MDDirectorApr 06Sale15.003,68655,2901,372,277Apr 10 08:41 PM
SHROTRIYA RAJESH C MDDirectorApr 05Sale15.3330,000459,9001,375,963Apr 05 04:00 PM
SHROTRIYA RAJESH C MDDirectorApr 04Sale15.0130,000450,3001,405,963Apr 05 04:00 PM
SHROTRIYA RAJESH C MDDirectorApr 03Sale15.1430,000454,2001,435,963Apr 05 04:00 PM
SHROTRIYA RAJESH C MDDirectorApr 02Sale15.6130,000468,3001,465,963Apr 02 05:43 PM
Riga Thomas JChief Operating OfficerApr 02Sale15.581,94830,350256,452Apr 02 05:30 PM
SHROTRIYA RAJESH C MDDirectorMar 29Sale16.1830,000485,4001,495,963Apr 02 05:43 PM
Turgeon Joseph W.CEO & PresidentMar 28Sale16.404,81078,884328,074Mar 28 05:12 PM
GUSTAFSON KURT AEVP & Chief Financial OfficerMar 28Sale16.354,35071,123187,193Mar 28 05:05 PM
SHROTRIYA RAJESH C MDDirectorMar 28Sale16.1930,000485,7001,525,963Mar 28 04:38 PM
SHROTRIYA RAJESH C MDDirectorMar 27Sale17.1030,000513,0001,555,963Mar 28 04:38 PM
SHROTRIYA RAJESH C MDDirectorMar 26Sale17.3430,000520,2001,585,963Mar 28 04:38 PM
Riga Thomas JChief Operating OfficerMar 26Sale17.412203,830251,476Mar 27 06:45 PM
GUSTAFSON KURT AEVP & Chief Financial OfficerMar 26Sale17.381,30022,594191,543Mar 27 06:33 PM
Turgeon Joseph W.CEO & PresidentMar 22Sale18.173,10056,327332,884Mar 23 06:43 PM
GUSTAFSON KURT AEVP & Chief Financial OfficerMar 22Sale18.132,64047,868192,843Mar 23 06:36 PM
Krassner Stuart MitchellDirectorMar 21Option Exercise2.5530,00076,50083,257Mar 23 06:46 PM
Krassner Stuart MitchellDirectorMar 21Sale18.644,20078,27879,057Mar 23 06:46 PM
SHROTRIYA RAJESH C MDDirectorMar 09Option Exercise2.55500,0001,275,0001,787,542Mar 12 06:05 PM
SHROTRIYA RAJESH C MDDirectorJan 09Option Exercise7.605,199,58439,510,7846,988,631Jan 11 09:27 PM
SHROTRIYA RAJESH C MDChairman & CEONov 30Option Exercise3.15100,000315,000214,684Dec 04 07:42 PM